retatrutide trial results news today 🚨 Big dropped — and here's why it actually matters. Yes, the “reta rats” have been talking about this molecule for years. But today's TRIUMPH-1 Phase 3 aren't Lilly's triple agonist, retatrutide, delivered

The combined primary endpoint of death from cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke occurred in 569 (6.5%) of patients in the semaglutide group versus 701 (8.0%) of patients in the placebo group, yielding a significant hazard ratio of 0.8 for a 20% relative risk reduction

The market is driven by the expanding clinical indication of these therapies, which are now evolving from handling Type 2 diabetes to long-term chronic weight management and even cardiovascular risk reduction

A confirmed diagnosis through a gastric emptying study is required to pursue legal action

Injectable: Key Differences While both forms contain semaglutide, there are important practical differences patients should understand before choosing between them

Abbotts Glucerna line continues to dominate protein-based GLP-1 support blends

Persistent or worsening reactions should be reported to your provider